2016
DOI: 10.5455/bcp.20150706034008
|View full text |Cite
|
Sign up to set email alerts
|

ADAMTS4, 5, 9, and 15 Expressions in the Autopsied Brain of Patients with Alzheimer's Disease: A Preliminary Immunohistochemistry Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 36 publications
1
2
0
Order By: Relevance
“…ADAMTS expression was discovered in the central nervous system (CNS) after various extensive research and is known to change in disease circumstances ( Miguel, Pollak & Lubec, 2005 ; Haddock et al, 2006 ; Gottschall & Howell, 2015 ). The downregulation of ADAMTS5 expression level in our A β group data was supported by previous study which demonstrated that ADAMTS4 and ADAMTS5 expressions were slightly under-expressed in case of AD which indicated the deficiency in the elimination of ECM in patients, which ultimately resulted in the accumulation of undesirable ECM compounds over time ( Pehlivan et al, 2016 ). Likewise, increase expression of ADAMTS5 from the combined treatment may assist in elevating the deterioration of ECM constituents, including A β senile plaque ( Pekny & Nilsson, 2005 ), which in turn, might aid recovery by the elimination of the CSPGs.…”
Section: Discussionsupporting
confidence: 85%
“…ADAMTS expression was discovered in the central nervous system (CNS) after various extensive research and is known to change in disease circumstances ( Miguel, Pollak & Lubec, 2005 ; Haddock et al, 2006 ; Gottschall & Howell, 2015 ). The downregulation of ADAMTS5 expression level in our A β group data was supported by previous study which demonstrated that ADAMTS4 and ADAMTS5 expressions were slightly under-expressed in case of AD which indicated the deficiency in the elimination of ECM in patients, which ultimately resulted in the accumulation of undesirable ECM compounds over time ( Pehlivan et al, 2016 ). Likewise, increase expression of ADAMTS5 from the combined treatment may assist in elevating the deterioration of ECM constituents, including A β senile plaque ( Pekny & Nilsson, 2005 ), which in turn, might aid recovery by the elimination of the CSPGs.…”
Section: Discussionsupporting
confidence: 85%
“…This finding may represent specific marker for the diagnosis of AD, and for the treatment of AD. Pehlivan et al [76] demonstrates that ADAMTS4 and 5 is slightly under-expressed in the brains from autopsied AD cases compared to control brains and suggests that ECM degradation is not promoted in AD brain. On the other hand, ADAMTS9 and 15 aggrecanases were not found to be expressed in brain sections of AD and control cases.…”
Section: The Possible Functions Of Adamts Proteases In Admentioning
confidence: 99%
“…Thus, Sato and colleagues [105] demonstrated that ADAMTS4 mRNA is induced by Aβ-treatment, suggesting a crucial role in AD progression. Additionally, investigation on human post-mortem brains of AD patients yielded reduced protein amounts of ADAMTS4 and 5, and complete absence of ADAMTS9, pointing to a malfunction of PN component degradation [106].…”
Section: Discussionmentioning
confidence: 99%